Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 10/20 | 0.43 |
| ▸ | SCN7A | Q01118 | 7/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.42 |
| ▸ | MLNR | O43193 | 3/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3064179 | 0.94 | HRH3 (0.45) | HRH3SCN9ASCN7AKCNH2SCN10A | |
| SCHEMBL3046922 | 0.89 | SCN9A (0.46) | HRH3SCN9ASCN7AKCNH2SCN10A | |
| SCHEMBL3064409 | 0.88 | HRH3 (0.44) | HRH3SCN9AMLNRLGALS8LGALS3 | |
| SCHEMBL3056188 | 0.88 | HRH3 (0.40) | HRH3SCN9ASCN7AKCNH2SCN10A | |
| SCHEMBL3055461 | 0.87 | SCN9A (0.54) | SCN9ASCN7AKCNH2SCN10ASCN5A | |
| Bromide SCHEMBL3061151 | 0.86 | STAT3 (0.45) | HRH3MLNR | |
| SCHEMBL3063218 | 0.86 | LGALS8 (0.38) | HRH3SCN9ASCN7AKCNH2SCN10A | |
| Bromide SCHEMBL3064130 | 0.86 | STAT3 (0.44) | HRH3MLNR | |
| SCHEMBL3057342 | 0.86 | L3MBTL1 (0.46) | HRH3MLNRLGALS8LGALS3 | |
| SCHEMBL3062018 | 0.85 | HRH3 (0.46) | HRH3SCN9ASCN7AKCNH2SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| EP-2207773-B1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMA CO LTD (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | HRH3 19/4885SCN9A 2616/4885SCN7A 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.